Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience (AYTU)
:AYTU
AYTU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $2.85
Previous CloseN/A
Volume5.78K
Average Volume (3M)184.70K
Market Cap
$15.67M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Sep 25, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding6,170,246
10 Day Avg. Volume186,373
30 Day Avg. Volume184,703
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.67Price Target Upside280.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients, with side effects comparable to placebo.
Market PotentialEXXUA is targeting the $22 billion U.S. prescription MDD market and aims to become an important treatment option for the 21 million Americans affected by MDD.
Revenue PerformanceAytu reported F3Q25 results with total revenue of $18.5M, exceeding the estimate of $13.7M.
Bears Say
Business DivestmentThe decline in total revenue was largely due to the divestment of the lower margin Consumer Health business.
Revenue DeclineADHD revenue, Aytu’s primary source of prescription revenue, experienced a decline and was below the analyst's estimate.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience’s price range in the past 12 months?
Aytu BioScience lowest stock price was $0.95 and its highest was $2.85 in the past 12 months.
What is Aytu BioScience’s market cap?
Aytu BioScience’s market cap is $15.67M.
When is Aytu BioScience’s upcoming earnings report date?
Aytu BioScience’s upcoming earnings report date is Sep 25, 2025 which is in 56 days.
How were Aytu BioScience’s earnings last quarter?
Aytu BioScience released its earnings results on May 14, 2025. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.37.
Is Aytu BioScience overvalued?
According to Wall Street analysts Aytu BioScience’s price is currently Undervalued.
Does Aytu BioScience pay dividends?
Aytu BioScience does not currently pay dividends.
What is Aytu BioScience’s EPS estimate?
Aytu BioScience’s EPS estimate is -0.03.
How many shares outstanding does Aytu BioScience have?
Aytu BioScience has 6,170,246 shares outstanding.
What happened to Aytu BioScience’s price movement after its last earnings report?
Aytu BioScience reported an EPS of $0.2 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 91.852%.
Which hedge fund is a major shareholder of Aytu BioScience?
Currently, no hedge funds are holding shares in AYTU
Company Description
Aytu BioScience
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AYTU Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth, positive net income, and successful strategic initiatives. Although there was a decline in gross margin due to higher cost inventory, the overall sentiment remains positive due to the company's operational efficiency and the success of the Aytu RxConnect platform.Read More>AYTU Stock 12 Month Forecast
Average Price Target
$9.67
▲(280.71%Upside)
Technical Analysis
Ownership Overview
4.15% Insiders
1.15% Mutual Funds
9.29% Other Institutional Investors
84.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---